Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17250
Corporate User License Price USD 750
Corporate User License Price INR 51750
Site License Price USD 500
Site License Price INR 34500
Request a Quote

Report Title

Albireo Pharma Inc (ALBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Albireo Pharma Inc (ALBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Albireo Pharma Inc (ALBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Albireo Pharma Inc (ALBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe medical conditions for which there is high unmet need. The company's lead product candidate, A4250 is a novel, minimally absorbed, orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor. The product is in a Phase III clinical trial for progressive familial intrahepatic cholestasis (PFIC), a rare, life-threatening genetic disorder affecting young children and potentially other orphan pediatric liver diseases. Albireo is located in Boston, Massachusetts, the US.

Albireo Pharma Inc (ALBO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Albireo Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Albireo Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Albireo to Raise USD10 Million in Venture Financing 12

Partnerships 13

Biodel Enters Into Co-Development Agreement With Yichang Chang Jiang Pharma 13

Merger 14

Biodel and Albireo Merges 14

Licensing Agreements 16

Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 16

Biodel Terminates Licensing Agreement With Aegis Therapeutics For ProTek And Intravail Technologies 17

Equity Offering 18

Albireo Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 18

Albireo Pharma Raises USD74.8 Million in Public Offering of Shares 19

Albireo Pharma Raises USD52 Million in Public Offering of Shares 21

Biodel Raises USD34.5 Million in Public Offering of Shares 23

Biodel to Raise up to USD15 Million in Private Placement of Shares 25

Albireo Pharma Raises USD19.2 Million in Public Offering of Shares 27

Biodel Completes Public Offering Of Shares For USD 20.5 Million 28

Biodel Completes Private Placement Of Units For USD 18.5 Million 29

Asset Transactions 30

Albireo Pharma Enters into Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat 30

Albireo Pharma Inc-Key Competitors 31

Albireo Pharma Inc-Key Employees 32

Albireo Pharma Inc-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Financial Announcements 34

Aug 07, 2018: Albireo reports second quarter 2018 financial results 34

May 17, 2018: Albireo Provides First Quarter 2018 Business Update 36

Mar 15, 2018: Albireo Reports Fourth Quarter and Year-End 2017 Financial Results 37

Nov 14, 2017: Albireo Reports Third Quarter 2017 Financial Results 39

Aug 21, 2017: Albireo Reports Second Quarter 2017 Financial Results 41

May 10, 2017: Albireo Reports First Quarter 2017 Financial Results 43

Mar 14, 2017: Albireo Reports 2016 Financial Results 45

Corporate Communications 47

Oct 10, 2018: Albireo appoints Simon Harford as chief financial officer and treasurer 47

Jul 25, 2018: Albireo appoints Patrick Horn as Chief Medical Officer 48

Jun 08, 2018: Albireo Names Anne Klibanski and Stephanie Okey As Board Directors 49

Sep 28, 2017: Albireo Elects Roger Jeffs to Board of Directors 50

Product News 51

05/28/2018: PIII Clinical Study Data on Chronic Constipation Treatment GOOFICE 5mg Tablet Will Be Presented at DDW2018 51

04/19/2018: World's First Bile Acid Transporter Inhibitor GOOFICE 5mg Tablet Launched in Japan 52

04/19/2018: Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting 53

01/19/2018: New drug approval of bile acid transporter inhibitor GOOFICE 5mg Tablet for chronic constipation was obtained in Japan 54

Product Approvals 55

Feb 01, 2017: Albireo Announces Submission of New Drug Application for Elobixibat in Japan 55

Clinical Trials 56

Jul 09, 2018: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment GOOFICE 5mg Tablet Published in The Lancet Gastroenterology & Hepatology 56

Jun 12, 2018: FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher 57

May 16, 2018: Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250 58

Apr 14, 2018: Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at The International Liver Congress 2018 59

Mar 28, 2018: Albireo to Present Clinical Data on A4250 at The International Liver Congress 2018 60

Oct 20, 2017: Final Results of Albireo's Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting 2017 61

Oct 03, 2017: Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting 2017 62

Sep 26, 2017: EMA's Paediatric Committee Agrees to Albireo's A4250 Pediatric Investigation Plan 63

May 18, 2017: Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC 64

Apr 27, 2017: Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017 66

Apr 22, 2017: Promising Pediatric Data for Albireo's A4250 to be Presented at The International Liver Congress 2017 67

Apr 05, 2017: EASL Selects Albireo's A4250 Data for Late Breaker Presentation 68

Appendix 69

Methodology 69

About GlobalData 69

Contact Us 69

Disclaimer 69

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Albireo Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Albireo Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Albireo Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Albireo Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Albireo to Raise USD10 Million in Venture Financing 12

Biodel Enters Into Co-Development Agreement With Yichang Chang Jiang Pharma 13

Biodel and Albireo Merges 14

Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 16

Biodel Terminates Licensing Agreement With Aegis Therapeutics For ProTek And Intravail Technologies 17

Albireo Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 18

Albireo Pharma Raises USD74.8 Million in Public Offering of Shares 19

Albireo Pharma Raises USD52 Million in Public Offering of Shares 21

Biodel Raises USD34.5 Million in Public Offering of Shares 23

Biodel to Raise up to USD15 Million in Private Placement of Shares 25

Albireo Pharma Raises USD19.2 Million in Public Offering of Shares 27

Biodel Completes Public Offering Of Shares For USD 20.5 Million 28

Biodel Completes Private Placement Of Units For USD 18.5 Million 29

Albireo Pharma Enters into Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat 30

Albireo Pharma Inc, Key Competitors 31

Albireo Pharma Inc, Key Employees 32

Albireo Pharma Inc, Other Locations 33

Albireo Pharma Inc, Subsidiaries 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Albireo Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person